Newron Pharmaceuticals SpA (NWRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Newron Pharmaceuticals SpA (NWRN) has a cash flow conversion efficiency ratio of 21.083x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF33.35 Million ≈ $42.17 Million USD) by net assets (CHF1.58 Million ≈ $2.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Newron Pharmaceuticals SpA - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Newron Pharmaceuticals SpA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NWRN total liabilities for a breakdown of total debt and financial obligations.
Newron Pharmaceuticals SpA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Newron Pharmaceuticals SpA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elitegroup Computer Systems Co Ltd
TW:2331
|
0.005x |
|
Tourism Finance Corporation of India Limited
NSE:TFCILTD
|
-0.041x |
|
Southern States Bancshares Inc
NASDAQ:SSBK
|
0.033x |
|
Barings Corporate Investors
NYSE:MCI
|
0.013x |
|
Guiyang Xintian Pharmaceutical Co Ltd
SHE:002873
|
0.039x |
|
Fleetpartners Group Ltd
AU:FPR
|
-0.084x |
|
Tupy S.A
SA:TUPY3
|
0.101x |
|
Volcon Inc
NASDAQ:VLCN
|
-0.265x |
Annual Cash Flow Conversion Efficiency for Newron Pharmaceuticals SpA (2005–2024)
The table below shows the annual cash flow conversion efficiency of Newron Pharmaceuticals SpA from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Newron Pharmaceuticals SpA stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF1.46 Million ≈ $1.84 Million |
CHF-17.61 Million ≈ $-22.27 Million |
-12.081x | -3663.28% |
| 2023-12-31 | CHF-29.91 Million ≈ $-37.81 Million |
CHF-10.14 Million ≈ $-12.82 Million |
0.339x | -57.12% |
| 2022-12-31 | CHF-14.03 Million ≈ $-17.74 Million |
CHF-11.09 Million ≈ $-14.02 Million |
0.791x | +121.46% |
| 2021-12-31 | CHF3.11 Million ≈ $3.93 Million |
CHF-11.45 Million ≈ $-14.47 Million |
-3.684x | -307.54% |
| 2020-12-31 | CHF17.25 Million ≈ $21.80 Million |
CHF-15.59 Million ≈ $-19.71 Million |
-0.904x | -51.35% |
| 2019-12-31 | CHF36.80 Million ≈ $46.52 Million |
CHF-21.98 Million ≈ $-27.78 Million |
-0.597x | -105.27% |
| 2018-12-31 | CHF54.84 Million ≈ $69.33 Million |
CHF-15.95 Million ≈ $-20.17 Million |
-0.291x | -134.45% |
| 2017-12-31 | CHF67.72 Million ≈ $85.62 Million |
CHF-8.40 Million ≈ $-10.62 Million |
-0.124x | +68.48% |
| 2016-12-31 | CHF49.75 Million ≈ $62.89 Million |
CHF-19.58 Million ≈ $-24.76 Million |
-0.394x | -13.58% |
| 2015-12-31 | CHF37.11 Million ≈ $46.92 Million |
CHF-12.86 Million ≈ $-16.26 Million |
-0.347x | -1.43% |
| 2014-12-31 | CHF29.26 Million ≈ $36.99 Million |
CHF-10.00 Million ≈ $-12.64 Million |
-0.342x | +32.56% |
| 2013-12-31 | CHF21.09 Million ≈ $26.66 Million |
CHF-10.69 Million ≈ $-13.51 Million |
-0.507x | -340.15% |
| 2012-12-31 | CHF27.61 Million ≈ $34.90 Million |
CHF5.83 Million ≈ $7.36 Million |
0.211x | +128.11% |
| 2011-12-31 | CHF6.58 Million ≈ $8.33 Million |
CHF-4.94 Million ≈ $-6.25 Million |
-0.750x | +52.17% |
| 2010-12-31 | CHF12.19 Million ≈ $15.41 Million |
CHF-19.13 Million ≈ $-24.18 Million |
-1.569x | -99.27% |
| 2009-12-31 | CHF29.28 Million ≈ $37.02 Million |
CHF-23.06 Million ≈ $-29.15 Million |
-0.787x | -80.96% |
| 2008-12-31 | CHF45.81 Million ≈ $57.92 Million |
CHF-19.93 Million ≈ $-25.20 Million |
-0.435x | -80.11% |
| 2007-12-31 | CHF57.40 Million ≈ $72.57 Million |
CHF-13.87 Million ≈ $-17.53 Million |
-0.242x | -70.22% |
| 2006-12-31 | CHF67.86 Million ≈ $85.79 Million |
CHF-9.63 Million ≈ $-12.17 Million |
-0.142x | +83.14% |
| 2005-12-31 | CHF17.02 Million ≈ $21.52 Million |
CHF-14.33 Million ≈ $-18.12 Million |
-0.842x | -- |
About Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more